Targeting BLyS in Systemic Lupus Erythematosus

Author(s): Yaoyang Liu, Antonio La Cava

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 6 , Issue 2 , 2012

Become EABM
Become Reviewer


Systemic lupus erythematosus (SLE) is a chronic disabling autoimmune disease that significantly impacts the quality of life of patients, and can associate with several complications including end-stage renal disease and shortened lifespan. A central component in the pathogenesis of SLE is the B-cell production of autoantibodies to multiple selfantigens. Since, B lymphocyte stimulator (BLyS) plays a key role in the selection, differentiation and survival of most B cells, it has been studied as a therapeutic target in SLE. After a gap of more than fifty years without new drugs being approved for this disease, the human neutralizing anti-BLyS monoclonal antibody belimumab has recently been approved by the FDA for SLE therapy. This review provides an overview on the targeting of BLyS in lupus animal models, the use of belimumab in human SLE, and relevant patents.

Keywords: Autoimmunity, biologics, clinical trials, BLyS/BAFF, systemic lupus erythematosus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [91 - 96]
Pages: 6
DOI: 10.2174/187221312800166831
Price: $65

Article Metrics

PDF: 6